Carbapenemase Producing Enterobacteriaceae (CPE) Prevention and Management Toolkit for Inpatient Areas

Similar documents
TRUST POLICY AND PROCEDURES FOR CARBAPENEM RESISTANT ENTEROBACTERIACEAE (CRE) AND CARBAPENEM RESISTANT ORGANISMS (CRO)

Infection Prevention and Control. Carbapenemase Producing Enterobacteriaceae (CPE)

CARBAPENEMASE PRODUCING ENTEROBACTERICAE (CPE): COMMUNITY TOOLKIT

Carbapenemase-Producing Enterobacteriaceae (CPE) and Carbapenemase-Producing Organisms (CPO)

HEALTHCARE ASSOCIATED INFECTIONS RISK ASSESSMENT PROCEDURE

Reducing the risk of healthcare associated infection

Reducing the risk of healthcare associated infection

Definitions. Healthcare Acquired Infection (HCAI)

Policy for the Control and Management of patients Colonised or Infected with Vancomycin resistant enterococci (VRE)

Carbapenemase Producing Coliforms (CPC)

Prevention and Control of Infection in Care Homes. Infection Prevention and Control Team Public Health Norfolk County Council January 2015

Early detection, management and control of carbapenemase-producing Enterobacteriaceae Policy V3.0

MRSA: Help us to help to help you

Preventing Further Spread of CPE

Alert Organisms Multi-Resistant Gram Negative Bacteria (MR-GNB) excluding MRSA

Assessing Evidence of Transmission and End of Transmission of Carbapenemase Producing Enterobacterales 1 (CPE)

SECTION 11.4 VANCOMYCIN RESISTANT ENTERCOCCUS (VRE)

Section J - Management of Patients with Multi Resistant Organisms:

Procedure for the Management and Control of Carbapenemase-producing Enterobacteriaceae (CPE)

01/09/2014. The very first requirement in a hospital is that it should do the sick no harm!!!!

Clostridium difficile Infection (CDI) Trigger Tool

Developed in response to: Health and Social Care Act 2008 Contributes CQC Core Standard Outcome 8

The Clatterbridge Cancer Centre. NHS Foundation Trust MRSA. Infection Control. A guide for patients and visitors

Clostridium difficile Infection (CDI) Trigger Tool

Policy Objective To provide Health Care Workers (HCWs) with details of the precautions necessary to minimise the risk of MRSA cross-infection.

Clostridium difficile Infection (CDI) in children (3-16 years ) Transmission Based Precautions

Infection Control Care Plan. Patient Demographic / label. Hospital: Ward:

Patient Demographic / Label. Infection Control Care Plan for a patient with MRSA

You have questions about CPE and CRE? Issued by the HSE Health Care Associated Infection and Antimicrobial Resistance Response Team.

Section J - Management of Patients with Multi Resistant Organisms:

Developed in response to: Best Practice Infection Prevention and Control

Prevention and Control of Carbapenem Resistant Enterobacteriaceae Infections

Approval Signature: Date of Approval: December 6, 2007 Review Date:

A guide for patients and visitors MRSA. A guide for patients and visitors

Prevention and Control of Multi-Resistant Gram Negative Bacteria including Acinetobacter; Infection Prevention and Control

INFECTION PREVENTION AND CONTROL. Multi- Resistant Gram Negative Bacilli Including E.coli and Acinetobacter Species Policy

Infection Control Care Plan for a patient with Group A Streptococcus

infection control MRSA Information for patients (Methicillin Resistant Staphylococcus aureus)

MRSA INFORMATION LEAFLET for patients and relatives. both in hospital and the community. MRSA is a type of

Infection Prevention and Control Carbapenemase producing Enterobacteriaceae (CPE) Policy

Everyone Involved in providing healthcare should adhere to the principals of infection control.

MRSA. Information for patients Infection Prevention and Control. Large Print

Disclosure Status (B) B Can be disclosed to patients and the public

Vancomycin-Resistant Enterococcus (VRE)

Kristi Felix RN, BSN, CRRN, CIC, FAPIC Infection Prevention Coordinator Madonna Rehabilitation Hospitals

Hand Hygiene: Train the Trainer. National Hand Hygiene Training Programme for Healthcare Workers in Community and Primary Care

MRSA. Information for patients Infection Prevention and Control

Enterobacteriaceae. Preventing the Spread of Carbapenemresistant. in LTCFs. Nimalie D. Sto ne, MD, MS CDC Division of Healthcare Quality Promotion

Glycopeptide-Resistant Enterococci (GRE) also known as Vancomycin-Resistant Enterococci (VRE) Policy

ASSESSMENT ACTIVITY ANSWER PACK

SUBJECT: Healthcare Associated Infection (HCAI) Reporting Template

National Hand Hygiene NHS Campaign

Clostridium difficile GDH positive (Glutamate Dehydrogenase) toxin negative

National Hand Hygiene NHS Campaign

Outbreak Management 2015

Policy for the control and management of patients colonised or infected with Meticillin Resistant Staphylococcus aureus (MRSA)

NHS GREATER GLASGOW & CLYDE CONTROL OF INFECTION COMMITTEE STANDARD OPERATING PROCEDURE (SOP) GROUP A STREPTOCOCCUS (Streptococcus pyogenes)

Methicillin Resistant Staphylococcus aureus (MRSA) screening and decolonisation

Infection Control Prevention Strategies. For Clinical Personnel

Clostridium difficile

METICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (M.R.S.A.) DECOLONISATION GUIDANCE PRIMARY CARE. Purpose of Issue/Description of Change

Infection Prevention Control Team

Vancomycin Resistant Enterococcus (VRE)

Infection Prevention and Control

TRUST POLICY AND PROCEDURE FOR THE MANAGEMENT AND CONTROL OF DIARRHOEA AND VOMITING (NOROVIRUS) INFECTIONS

Lightning Overview: Infection Control

Checklists for Preventing and Controlling

Infection Prevention and Control and Isolation Authored by: Infection Prevention and Control Department

Preventing Infection Workbook

Take Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home

1/28/2014. Take Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home. Thank you to AANAC

NOSOCOMIAL INFECTION : NURSES ROLE IN MINIMIZING TRANSMISSION

INCREASED INCIDENT /OUTBREAK OF DIARRHOEA AND/OR VOMITING

Toolkit for the early detection, management and control of carbapenemase-producing Enterobacteriaceae in Scottish acute settings

Northumbria Healthcare NHS Foundation Trust. Infection Control Information for Patients and Visitors. Issued by The Infection Control Team

: Hand. Hygiene Policy NAME. Author: Policy and procedure. Version: V 1.0. Date created: 11/15. Date for revision: 11/18

MRSA Meticillin-resistant

Glycopeptide/Vancomycin Resistant Enterococci (GRE/VRE) Policy

National Hand Hygiene NHS Campaign

What you can do to help stop the spread of MRSA and other infections

Guideline with MDRO or C-Diff Patient Age Group: ( ) N/A (x ) All Ages ( ) Newborns ( ) Pediatric ( ) Adult

Hereford Hospitals NHS Trust

How to Add an Annual Facility Survey

Guidelines for the Management of C. difficile Infections in. Healthcare Settings. Saskatchewan Infection Prevention and Control Program November 2015

2014 Annual Continuing Education Module. Contents

MRSA. Information for patients and carers. Delivering the best in care. UHB is a no smoking Trust

INFECTION PREVENTION AND CONTROL

Guidance for Care Homes SAMPLE. Preventing Infection Workbook. Guidance for Care Homes. 10th Edition. Name. Job Title 1

Procedures for Prevention and Management of MRSA / Carbapenemase-producing Enterobacteriaceae (Antimicrobial Resistance) in Care Settings in Shetland

& ADDITIONAL PRECAUTIONS:

Contamination control: part 2 a vet nurse s critical role

MRSA in Holland What is Behind the Success Gertie van Knippenberg-Gordebeke

Includes GP flow chart & out of hours protocols. Page 1 of 11

The Role of Isolation and Contact Precautions in the Elimination of Transmission of MRSA

INFECTION C ONTROL CONTROL CONTROL EDUCATION PROGRAM

The Management of Extended Spectrum Beta Lactamase-Producing Organisms Policy. Infection Prevention and Control

IC CONTACT and CONTACT PLUS PRECAUTIONS REV. JULY 2017

Healthcare Acquired Infections

Antibiotic Use and Resistance in Nursing Homes

Isolation Care of Patients in Isolation due to Infection or Disease

Transcription:

Carbapenemase Producing Enterobacteriaceae (CPE) Prevention and Management Toolkit for Inpatient Areas This toolkit includes examples advice leaflets and forms which may be helpful for use by teams or adapted for use locally Version 1.0: June 2013

Healthcare worker information leaflet: Carbapenemase Producing Enterobacteriaceae (CPE) What are Carbapenemase Producing Enterobacteriaceae (CPE)? Carbapenemase Producing Enterobacteriaceae (CPE) are a type of extremely antibiotic resistant bacteria. The Enterobacteriaceae are a family of Gram negative bacteria (sometimes called coliforms) which are part of the normal bacterial gut flora. They include common pathogens such as E. coli, Klebsiella sp, Proteus sp and Enterobacter spp. These organisms are some of the most common causes of many infections such as urinary tract infections, intra-abdominal infections and bloodstream infections. Carbapenems are a class of very broad spectrum intravenous antibiotics which are reserved for serious infections or when other therapeutic options have failed. What causes Carbapenem Resistance and what are CPE and CRE? Enterobacteriaceae which have become resistant to carbapenems are sometimes called Carbapenem Resistant Enterobacteriaceae (CRE). There are different ways in which this resistance can occur, but the most concerning group from a clinical and infection control perspective are those organisms which carry a carbapenemase enzyme that breaks down carbapenem antibiotics. This type of CRE is called Carbapenemase Producing Enterobacteriaceae (CPE) and it is the type which spreads most easily and has caused most outbreaks worldwide. Why are CPE of concern? Enterobacteriaceae are the commonest cause of urinary tract infections, bloodstream infections (bacteraemia) and intra-abdominal infections, all of which can be life-threatening. Carbapenems have for years been the last line antibiotics for infections caused by multi-drug resistant Enterobacteriaceae. This has now changed with the development of CPE, which are also usually resistant to most other antibiotic classes e.g. all penicillin-type antibiotics, ciprofloxacin, gentamicin and others. This leaves very few and sometimes no options for antibiotic therapy. How common are CPE? Over the last decade CPE have spread throughout the world and are now endemic in healthcare facilities in many countries. They are currently uncommon in the UK and most cases have been associated with hospitalisation abroad. However, the prevalence of CPE is increasing and there are already areas in the UK where CPE can be considered endemic. There is a real risk that CPE could become endemic in UK health systems. It is therefore extremely important to identify patients who have been hospitalised abroad as this is currently the greatest risk for CPE carriage. Healthcare worker information leaflet: Carbapenemase Producing Enterobacteriaceae (CPE)

Infection Control measures to be taken when an individual is identified as colonised/infected with a CRE or CPE As usual, the most important measure to prevent spread is good hand hygiene with soap and water and/or alcohol hand gel. Patients must be isolated in single rooms with ensuite facilities, and contact precautions used when attending to these patients. Please refer to the daily checklist for patients colonised with CPE. Further advice should be sought from the Infection Prevention and Control Team. It is important that communication is maintained between the hospital and community care teams, and between teams within the hospital. Healthcare worker information leaflet: Carbapenemase Producing Enterobacteriaceae (CPE)

Patient Details Name: DOB: CHI: Ward: Carbapenemase Producing Enterobacteriaceae CPE Risk Assessment As part of a strategy to prevent spread of CPE the following advice should be taken and this form completed on admission for all patients. This form should be kept in the patient s medical record and will be audited for presence and completion. Is the patient in any of the following groups? Patients transferred from any hospital outside Scotland Patients hospitalised outside Scotland in the last 12 months Holiday dialysis patients Previous known CPE colonisation/ infection Yes: Yes: Yes: Yes: If Yes to one or more of the above, the patient is at increased risk of CPE carriage and the actions below should be taken To be completed by local IPCT Signature Designation Date Ward Site Carbapenemase Producing Enterobacteriaceae CPE Risk Assessment

PRACTICAL ADVICE ON HOW TO SCREEN FOR CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE (CPE) A rectal swab is the sample of choice for CPE screening. Alternatively, a stool sample can be sent (e.g. in children or if patient refuses a rectal swab). A rectal swab should be taken using a routine bacteriology swab. The swab is inserted gently into the rectum, and rotated gently to ensure faecal material is sampled. Place the swab back into the transport medium and transport the specimen to the microbiology laboratory. Stool samples should be collected in the same way as they are for routine culture. Patients with wounds or lesions should have these swabbed using a bacteriology swab (in addition to the rectal swab or stool sample). Patients with urinary catheters should have a Catheter Specimen Urine sent (in addition to the rectal swab or stool sample). Use a routine Bacteriology request form. Request M,C&S and in the clinical details write: For Carbapenemase Producing Enterobacteriaceae (CPE) screen If the screen is positive the Infection Prevention and Control Team will communicate further with you. Please note that if the patient requires an MRSA screen as well, then separate samples need to be sent for MRSA and CPE screening. Practical advice on how to screen for Carbapenemase Producing Enterobacteriaceae (CPE)

Checklist for Patients with CPE Colonisation/Infection: Admission date / / Date of sample collected / / Date or result reported / / Date ward notified / / Please initial which measures have been applied and review daily for duration of patient stay DATE Patient isolated in side room with ensuite facilities with door closed and appropriate contact precautions door poster displayed If patient moved from bay to side room, whole bay terminally cleaned including horizontal surfaces (with Actichlor Plus) & all screens changed in bay Patient Placement Infection Control Measures Information and Treatment If unable to isolate, inform bed manager and IPCN immediately to obtain single room. Document this event in patient notes. Note: out of hours bed manager must contact duty microbiologist if patient isolation not possible Alcohol hand rub in patient s room/bed space All staff/visitors must perform hand hygiene with alcohol hand rub before leaving the room. Note: if staff/visitors hands are visibly soiled soap & water must be used before applying alcohol hand rub All staff to wear gloves and aprons for direct contact with patient or their environment and remove these after attending patient Note: where any part of staff uniform not protected by an ordinary apron is expected to come into contact with the patient, a long-sleeved disposable gown should be used e.g. when assisting movement in a dependent patient Minimise amount of equipment in patient s room Remove fans or other equipment that could exacerbate any environmental contamination Patient notes and charts to be kept outside patient room Dedicate patient care equipment (stethoscope, BP manometer, thermometer) in patient s room Nursing and domestic staff to commence environmental cleaning/disinfection of room and equipment using a solution of sodium hypochlorite with concentration of 1000 ppm e.g. Actichlor Plus. Room to be cleaned daily. Frequently touched surfaces and toilets to be cleaned twice daily and when visibly soiled. Check patients do not have invasive devices that are no longer clinically required or that have signs of inflammation/infection Patient informed of result Patient Information Leaflet provided and explained (document in notes. Include family, if patient consents) Education given at ward level by a member of the IPCT on CPE Ward staff provided with information sheet on CPE Daily washing of patient with Chlorhexidine gluconate 4% aqueous solution (e.g. Hibiscrub) if advised by IPC. Antibiotic therapy reviewed by patient s medical team Checklist for patients with CPE Colonisation/Infection

Patient Information Leaflet Carbapenemase Producing Enterobacteriaceae (CPE) What does CPE mean? CPE stands for Carbapenemase Producing Enterobacteriaceae. This is the name given to a group of germs (bacteria) which have become very resistant to antibiotics including those called carbapenems. This germ usually lives harmlessly in the gut of all humans and animals and helps us digest our food. However, if they get into the wrong place such as the bladder or bloodstream they can cause infection. Why does carbapenem resistance matter? Carbapenem antibiotics are a powerful group of antibiotics that can only be given in hospital directly into the blood stream with a needle. Until now, they were antibiotics that could always be relied upon when other antibiotics failed. Do CPE need to be treated and, if so, how? Because the Enterobacteriaceae normally live in the gut without causing problems (this is called colonisation ) they do not always need to be treated. However, if they cause an infection then treatment is required. Infections caused by CPE can be very difficult to treat with antibiotics. This is why it is so important to prevent the spread of CPE. How will I know if I am at risk of CPE? The main risk factor for CPE is having been in a hospital abroad and being exposed to other carriers of CPE. If you have these risk factors we will ask to screen you. How do you screen for CPE? The screening method requires a swab to be inserted just into your rectum (bottom) and the specimen will be sent to see what germs grow. Alternatively a sample of faeces can be sent and sometimes other swabs may also be required. A result will normally take 48-72 hours to be available and the clinical team who are treating you will inform you directly of the results. Advantages of CPE screening It will tell us whether you carry this organism. This means that all appropriate precautions can be taken when you are receiving healthcare to keep the risk of infection to a minimum. What if I have CPE? CPE do not usually cause problems to people who are otherwise fit and healthy, and you may not suffer any effects from carrying CPE. However, antibiotic treatment to prevent or treat any infections may be more complicated when you are carrying CPE. If you are in hospital then you will be asked to remain in a single room for the duration of your stay and staff caring for you will carry out additional infection prevention and control precautions. How can the spread of CPE be prevented? Healthcare workers will wash their hands or use alcohol hand gel regularly. They will use gloves and aprons when caring for you to help prevent the spread of any germs. The most important measure is to wash your hands and use alcohol hand gel regularly. Where can I find more information? If you would like any further information please speak to a member of staff, who may contact the Infection Prevention and Control Team for you. The Health Protection Agency website is another source of information: http://www.hpa.org.uk/topics/infectiousdiseases/infectionsaz/carbapenemresistance/ Patient Information Leaflet: Carbapenemase Producing Enterobactericeae (CPE)

Patient Details Name: DOB: CHI: Ward: Patient Transfer Form This form must be filled out for transfer to accepting facility with information communicated prior to or with transfer Please attach copies of latest culture reports with susceptibilities if available Name/ Address of Sending Facility Sending Ward Sending Facility Phone Is the patient currently isolated? Yes: Does the patient require isolation in receiving location? Yes: Does the patient/resident currently have any of the following? Cough or requires suctioning Diarrhoea Vomiting Incontinent of urine or stool Open wounds or wounds requiring dressing change Drainage (source).. PVC (Date inserted...) Central line /PICC (Date inserted...) Hemodialysis catheter Urinary catheter (Date inserted. ) Suprapubic catheter Tracheostomy Radiological Inserted Gastro tube (RIG) (Date inserted....) Does patient currently have an infection, colonisation OR a history of positive culture of a multidrug-resistant organism or other organism of epidemiological significance? Methicillin-resistant Staphylococcus aureus (MRSA) Vancomycin-resistant Enterococcus (VRE) Clostridium difficile Multi-drug resistant organism Carbapenemase Producing Enterobacteriaceae (CPE) Other: Is the patient currently on antibiotics? Yes: Colonization or history Active infection on Treatment Antibiotic name and dose Treatment for: Start date Anticipated stop date Printed Name of person completing the form Signature Date If information communicated prior to transfer: Name and phone of individual at receiving facility Patient Transfer Form)